The Europe 11 cohort saw the greatest volume of life science companies in EF history. We’re realizing that life science companies have unique timelines and funding requirements. We expect this investment trend to continue and want to provide the best possible environment for our founders to succeed. It’s in that light that we’re so excited to partner with RebelBio, SOSV’s London based venture capital program which invests exclusively in early stage science-based, tech-enabled startups. Together we believe we’ll be able to better create a new wave of leading life science companies. EF bringing our expertise in talent investing and RebelBio in their scientific resources and tailored networks.
This partnership will roll out with the upcoming Europe 12 Launch Selection cycle. At the end of the team-building phase of our Form programme, EF and RebelBio will then select life science teams for a “Joint Investment Offer”, which will be comprised of equity investment, expert mentorship, working space / lab access and the fundraising resources of both investors. This partnership represents the second of its kind. Earlier this year we announced a similar partnership with HAX (another SOSV program) which has already supercharged the trajectory of many EF hardware companies.
Already we’ve seen the enormous value RebelBio can provide to our founders. They’ve helped source lab space across Europe, made introductions to specialist investors and advised on technical and strategic challenges. I and the entire EF Europe team are thrilled to see where this partnership can go.